ENTACAPONE, (Z)-

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H15N3O5
Molecular Weight	305.286
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(CC)C(=O)C(=C/C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N

InChI

InChIKey=JRURYQJSLYLRLN-YHYXMXQVSA-N

InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5-

HIDE SMILES / InChI

Molecular Formula	C14H15N3O5
Molecular Weight	305.286
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB00494
Curator's Comment: Description was created based on several sources, including http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000171/WC500033075.pdf

Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor. The mechanism of action of entacapone is believed to be through its ability to inhibit COMT in peripheral tissues, altering the plasma pharmacokinetics of levodopa. When entacapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to a greater reduction in the manifestations of parkinsonian syndrome. Entacapone is used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off".

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Catechol O-methyltransferase 21 Target ID: CHEMBL2023 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9681662	Inhibitor 8297	151.0 nM [IC50]
NCI-H1299 3 Target ID: CHEMBL612255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24148818	Inhibitor 8297	76.8 µM [IC50]
Mycobacterium tuberculosis 21 Target ID: CHEMBL360 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19578428	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Parkinson's disease 226 Sources: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/comtan.pdf	Secondary		Approved 8429	Comtan Approved Use Comtan is indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with Parkinson’s disease Launch Date 1999

C_max

Value	Dose	Co-administered	Analyte	Population
1095 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10492060	200 mg 10 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: LEVODOPA\|CARBIDOPA	LEVODOPA\|CARBIDOPA	ENTACAPONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1325 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10492060	200 mg 8 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: LEVODOPA\|CARBIDOPA	LEVODOPA\|CARBIDOPA	ENTACAPONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020796s15lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA\|CARBIDOPA	LEVODOPA\|CARBIDOPA	ENTACAPONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1989 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10492060	200 mg 10 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: LEVODOPA\|CARBIDOPA	LEVODOPA\|CARBIDOPA	ENTACAPONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2084 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10492060	200 mg 8 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: LEVODOPA\|CARBIDOPA	LEVODOPA\|CARBIDOPA	ENTACAPONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10492060	200 mg 10 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: LEVODOPA\|CARBIDOPA	LEVODOPA\|CARBIDOPA	ENTACAPONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10492060	200 mg 8 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: LEVODOPA\|CARBIDOPA	LEVODOPA\|CARBIDOPA	ENTACAPONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020796s15lbl.pdf			ENTACAPONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
25 mg single, intravenous Dose: 25 mg Route: intravenous Route: single Dose: 25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8039535	healthy, 24 years (range: 22-28 years) n = 12 Health Status: healthy Age Group: 24 years (range: 22-28 years) Sex: M Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/8039535	Sources: https://pubmed.ncbi.nlm.nih.gov/8039535
2400 mg 1 times / day steady, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: steady Dose: 2400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	healthy n = 8 Health Status: healthy Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	Other AEs: Abdominal pain, Loose stools... Other AEs: Abdominal pain Loose stools Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
2400 mg 1 times / day steady, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: steady Dose: 2400 mg, 1 times / day Co-administed with:: levodopa/carbidopa(14 days) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy n = 15 Health Status: unhealthy Condition: Parkinson’s Disease Population Size: 15 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	Other AEs: Abdominal pain, Loose stools... Other AEs: Abdominal pain Loose stools Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
800 mg single, oral Highest studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy Health Status: unhealthy Condition: Parkinson’s Disease Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy n = 603 Health Status: unhealthy Condition: Parkinson’s Disease Population Size: 603 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	Disc. AE: Psychiatric symptom, Diarrhea... AEs leading to discontinuation/dose reduction: Psychiatric symptom (2%) Diarrhea (2%) Dyskinesia (2%) Nausea (2%) Abdominal pain (1%) Hyperkinesia (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF

AEs

AE	Significance	Dose	Population
Abdominal pain		2400 mg 1 times / day steady, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: steady Dose: 2400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	healthy n = 8 Health Status: healthy Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Loose stools		2400 mg 1 times / day steady, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: steady Dose: 2400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	healthy n = 8 Health Status: healthy Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Abdominal pain		2400 mg 1 times / day steady, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: steady Dose: 2400 mg, 1 times / day Co-administed with:: levodopa/carbidopa(14 days) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy n = 15 Health Status: unhealthy Condition: Parkinson’s Disease Population Size: 15 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Loose stools		2400 mg 1 times / day steady, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: steady Dose: 2400 mg, 1 times / day Co-administed with:: levodopa/carbidopa(14 days) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy n = 15 Health Status: unhealthy Condition: Parkinson’s Disease Population Size: 15 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Abdominal pain	1% Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy n = 603 Health Status: unhealthy Condition: Parkinson’s Disease Population Size: 603 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Diarrhea	2% Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy n = 603 Health Status: unhealthy Condition: Parkinson’s Disease Population Size: 603 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Dyskinesia	2% Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy n = 603 Health Status: unhealthy Condition: Parkinson’s Disease Population Size: 603 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Hyperkinesia	2% Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy n = 603 Health Status: unhealthy Condition: Parkinson’s Disease Population Size: 603 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Nausea	2% Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy n = 603 Health Status: unhealthy Condition: Parkinson’s Disease Population Size: 603 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Psychiatric symptom	2% Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy n = 603 Health Status: unhealthy Condition: Parkinson’s Disease Population Size: 603 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:4798	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4798
ChemicalBook	CB5726435	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5726435
MolPort	MolPort-003-847-054	https://www.molport.com/shop/molecule-link/MolPort-003-847-054
Selleck Chemicals	entacapone	http://www.selleckchem.com/products/entacapone.html
ZINC	ZINC000035342787	http://zinc15.docking.org/substances/ZINC000035342787
eMolecules	27345033	https://www.emolecules.com/cgi-bin/more?vid=27345033

PubMed

Title	Date	PubMed
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA.	2000 Mar	10762340
Entacapone.	2000 Sep	10981253
Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.	2001	11244274
Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.	2003 Feb	12538800
An artist's view of drug-induced hallucinosis.	2003 Jul	12815666
Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases.	2005 Jul	15802387
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.	2008 Dec	18722529
Mirtazapine-associated urinary retention.	2010 Summer	20686159

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose of Comtan (entacapone) is one 200 mg tablet administered concomitantly with each levodopa and carbidopa dose to a maximum of 8 times daily (200 mg x 8 = 1,600 mg per day). Comtan should always be administered in association with levodopa and carbidopa. Entacapone has no antiparkinsonian effect of its own.

Route of Administration: Oral

In Vitro Use Guide

Kinetic assays indicate that Comtan inhibits InhA activity by 47.0% at an entacapone concentration of approximately 80 uM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:23:57 GMT 2023` Edited by `admin` on `Fri Dec 15 17:23:57 GMT 2023`
Record UNII	4X96VV9HUQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ENTACAPONE, (Z)-

Common Name

English

(Z)-2-CYANO-3-(3,4-DIHYDROXY-5-NITROPHENYL)-N,N-DIETHYL-2-PROPENAMIDE

Systematic Name

English

ENTACAPONE RELATED COMPOUND A

Common Name

English

ENTACAPONE IMPURITY A [EP IMPURITY]

Common Name

English

2-PROPENAMIDE, 2-CYANO-3-(3,4-DIHYDROXY-5-NITROPHENYL)-N,N-DIETHYL-, (Z)-

Systematic Name

English

ENTACAPONE RELATED COMPOUND A [USP-RS]

Common Name

English

(Z)-ENTACAPONE

Common Name

English

(2Z)-2-CYANO-3-(3,4-DIHYDROXY-5-NITROPHENYL)-N,N-DIETHYLPROP-2-ENAMIDE

Systematic Name

English

ENTACAPONE RELATED COMPOUND A [USP IMPURITY]

Common Name

English

Code System Code Type Description

RS_ITEM_NUM

1235944

Created by admin on Fri Dec 15 17:23:57 GMT 2023 , Edited by admin on Fri Dec 15 17:23:57 GMT 2023

PRIMARY

PUBCHEM

21864625

Created by admin on Fri Dec 15 17:23:57 GMT 2023 , Edited by admin on Fri Dec 15 17:23:57 GMT 2023

PRIMARY

FDA UNII

4X96VV9HUQ

Created by admin on Fri Dec 15 17:23:57 GMT 2023 , Edited by admin on Fri Dec 15 17:23:57 GMT 2023

PRIMARY

CAS

145195-63-7

Created by admin on Fri Dec 15 17:23:57 GMT 2023 , Edited by admin on Fri Dec 15 17:23:57 GMT 2023

PRIMARY

Related Record Type Details


					4975G9NM6T

ENTACAPONE

PARENT -> METABOLITE

Comments:

Active in vitro,but contribution should be little due to low plasma level

Qualification:

PLASMA

Related Record Type Details


					4975G9NM6T

ENTACAPONE

PARENT -> IMPURITY

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:

Details

SMILES

InChI

DescriptionSources: http://www.drugbank.ca/drugs/DB00494Curator's Comment: Description was created based on several sources, including http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000171/WC500033075.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.drugbank.ca/drugs/DB00494
Curator's Comment: Description was created based on several sources, including http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000171/WC500033075.pdf

C_max

T_1/2

F_unbound